Objective To investigate the effects of USP4 on the proliferation of human hypertrophic scar fibroblasts(HSFB).Methods HSFB were cultured in vitro.The fourth generation of HSFB in logarithmic growth phase was selected in the experiment.HSFB were intervened by Vialinin A which was the inhibitor of USP4 for 0,12,24,48 h,then collected cells and the their expression of USP4 and TβRI and Smad7 protein was detected by Western blot.MTT assay was used to detect the effect of Vialinin A on the proliferation of HS fibroblasts and the cells were divided into experimental group and control group(without intervention).Results After treatment with Vialinin A in HSFB,the expression of USP4 and TβRI protein in HSFB decreased gradually,especially in 12 h(P<0.05),and Smad7 protein expression was increased gradually(P<0.05).The proliferative activity of intervened HSFB reduced gradually,the difference between experimental group and control group was statistically significant(P<0.05).Conclusion USP4 might inhibit the proliferation of scar cells and down-regulation of USP4 expression in hyperplastic scar fibroblasts,which can slow proliferative activity of intervened HSFB by regulating TGF-β/Smad signaling pathway.

Adenocarcinoma ; diagnosis ; Cervical Intraepithelial Neoplasia ; diagnosis ; Diagnosis, Differential ; Female ; Humans

Claudins ; Humans ; Inflammatory Bowel Diseases

Cervical Intraepithelial Neoplasia ; diagnosis ; metabolism ; pathology ; Cervix Uteri ; metabolism ; pathology ; Cyclin-Dependent Kinase Inhibitor p16 ; metabolism ; Diagnosis, Differential ; Female ; Humans ; Ki-67 Antigen ; metabolism ; Membrane Proteins ; metabolism ; Neoplasm Invasiveness ; Uterine Cervical Dysplasia ; diagnosis ; metabolism ; pathology ; Uterine Cervical Neoplasms ; diagnosis ; metabolism ; pathology

Child ; Erythropoietin ; adverse effects ; Humans ; Male ; Recombinant Proteins ; Red-Cell Aplasia, Pure ; chemically induced

Adenoma ; pathology ; Carcinoma ; pathology ; Carcinoma in Situ ; pathology ; Gastric Mucosa ; pathology ; Humans ; Neoplasm Invasiveness ; Precancerous Conditions ; pathology ; Stomach Neoplasms ; classification ; pathology

Adult ; Audiometry, Pure-Tone ; Case-Control Studies ; Evoked Potentials, Auditory, Brain Stem ; Hearing Loss, Noise-Induced ; diagnosis ; physiopathology ; Humans ; Male ; Middle Aged ; Noise, Occupational

ObjectiveTo evaluate the safety and efficacy of urinary kallidinogenase for recombinant tissue-type plasminogen activator (rt-PA) intravenous thrombolytic treatment in patients with acute cerebral infartion MethodsA randomized control study was applied. All 44 patients with acute cerebral infartion were randomized 1:1 to the experimental group (22 cases) and the control group (22 cases). Patients were administrated rt-PA(0. 9 mg/kg)in control group, and patients were given urinary kallidinogenase by intravenous drip (0.15 PNAU/d, for 7 days) after rt-PA intravenous thrombolytic treatment (0.9 mg/kg)in experimental group. The main evaluation index was the incidence of symptomatic intraeerebral hemorrhage within 24 hours, and the secondary assessing items were NIHSS and BI. ResultsThere was 1 case (4.6%) with symptomatic intracerebral hemorrhage in the experimental group and 2 (9.1%) in the control group (X2 =0.00, P= 1.000),and reinfarction rate showed a decreasing tendency in experimental group (18.2% vs. 31.8%, X2=1.091,P=0.296). Compared with the control group, the NIHSS scores were significantly lower 1,21,90 days after thrombolytic therapy (t=2.119, 2.913, 2.187);P=0.041, 0.0 06, 0.042),and the BI scores were obviously higher at 90 days after thrombolytic therapy in experimental group(t= 2.39,P= 0.012). ConclusionsWithout increasing the risk of intracerebral hemorrhage, urinary kallidinogenase may improve the curative effect for rt-PA intravenous thrombolytic treatment in patients with acute cerebral infartion

Budd-Chiari Syndrome ; complications ; Humans ; Seizures ; complications

Child ; Humans ; Vesico-Ureteral Reflux ; therapy